In 2008, the US Food and Drug Administration (FDA) issued guidance requiring robust assessment of cardiovascular safety for all antidiabetic drugs to be licensed in the future. Here, we review the circumstances giving rise to the FDA guidance and describe the characteristics of clinical trials registered on ClinicalTrials.gov in the 36 months before and after the guidance was issued. We noted a doubling in the number of cardiovascular outcome trials registered and a sixfold increase in the me...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice.
If you are the owner of this record, you can report an update to it here: Report update to this record